Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records.

Brownstein JS, Murphy SN, Goldfine AB, Grant RW, Sordo M, Gainer V, Colecchi JA, Dubey A, Nathan DM, Glaser JP, Kohane IS.

Diabetes Care. 2010 Mar;33(3):526-31. doi: 10.2337/dc09-1506. Epub 2009 Dec 15.

2.

Rosiglitazone and myocardial infarction in patients previously prescribed metformin.

Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, Wright JM.

PLoS One. 2009 Jun 27;4(6):e6080. doi: 10.1371/journal.pone.0006080. Erratum in: PLoS One. 2010;5(7). doi: 10.1371/annotation/3330720e-5520-4211-91f3-d3b3d20e9804.

3.

The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.

Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003.

PMID:
20110009
4.

Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.

Winkelmayer WC, Setoguchi S, Levin R, Solomon DH.

Arch Intern Med. 2008 Nov 24;168(21):2368-75. doi: 10.1001/archinte.168.21.2368.

PMID:
19029503
5.

Coronary heart disease outcomes in patients receiving antidiabetic agents.

McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.

Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):711-25.

PMID:
17551989
6.

A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes.

Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S.

Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1065-71.

PMID:
17674425
7.

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group.

N Engl J Med. 2007 Jul 5;357(1):28-38. Epub 2007 Jun 5.

8.

A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.

Cobitz A, Zambanini A, Sowell M, Heise M, Louridas B, McMorn S, Semigran M, Koch G.

Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):769-81. doi: 10.1002/pds.1615.

PMID:
18613278
9.

Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.

Loebstein R, Dushinat M, Vesterman-Landes J, Silverman B, Friedman N, Katzir I, Kurnik D, Lomnicky Y, Kokia E, Halkin H.

J Clin Pharmacol. 2011 Feb;51(2):173-80. doi: 10.1177/0091270010368281. Epub 2010 May 19.

PMID:
20484611
10.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
11.

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.

Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM.

BMJ. 2009 Aug 18;339:b2942. doi: 10.1136/bmj.b2942.

12.

Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project.

Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, Havranek EP, Krumholz HM.

Diabetes Care. 2005 Jul;28(7):1680-9.

PMID:
15983320
13.

An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients.

Koro CE, Fu Q, Stender M.

Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):989-96. doi: 10.1002/pds.1640.

PMID:
18759378
14.

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P.

BMJ. 2009 Dec 3;339:b4731. doi: 10.1136/bmj.b4731.

15.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
16.
17.

Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.

Stockl KM, Le L, Zhang S, Harada AS.

Pharmacoepidemiol Drug Saf. 2009 Feb;18(2):166-74. doi: 10.1002/pds.1700.

PMID:
19109802
18.

A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

Tilden DP, Mariz S, O'Bryan-Tear G, Bottomley J, Diamantopoulos A.

Pharmacoeconomics. 2007;25(1):39-54. Erratum in: Pharmacoeconomics. 2007;25(3):237.

PMID:
17192117
19.

Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.

Dahabreh IJ, Economopoulos K.

Clin Trials. 2008;5(2):116-20. doi: 10.1177/1740774508090212. Erratum in: Clin Trials. 2008;5(5):559. Economopoulos, K [added].

PMID:
18375649
20.

Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review.

Wang AT, McCoy CP, Murad MH, Montori VM.

BMJ. 2010 Mar 18;340:c1344. doi: 10.1136/bmj.c1344. Review.

Items per page

Supplemental Content

Write to the Help Desk